Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Combination Details

General Information of the Combination (ID: C74471)
Name Flavopiridol   NP Info  + Vorinostat   Drug Info 
Structure +
Disease
Acute myeloid leukemia [ICD-11: 2A60]
Phase 1 [1]
Chronic myelogenous leukaemia [ICD-11: 2A20]
Phase 1 [1]
Anemia [ICD-11: 3A9Z]
Phase 1 [1]
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Phase 1 [2]
Adrenocortical carcinoma [ICD-11: 2D11]
Investigative [3]
    Click to Show/Hide the Whole Disease Information of This Combination
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [3]
                    Molecule(s)
                    Regulation
Down-regulation Expression CCNB1  Molecule Info 
Pathway MAP
Down-regulation Expression MAD2L1  Molecule Info 
Pathway MAP
Down-regulation Expression MMP-2  Molecule Info 
Pathway MAP
                    In-vitro Model CHLA-15 CVCL_6594 Neuroblastoma Homo sapiens
CHLA-20 CVCL_6602 Neuroblastoma Homo sapiens
SK-N-BE(1) CVCL_9898 Neuroblastoma Homo sapiens
SK-N-RA CVCL_AQ53 Neuroblastoma Homo sapiens
LA-N-6 CVCL_1363 Neuroblastoma Homo sapiens
CHLA-136 CVCL_6590 Neuroblastoma Homo sapiens
CHLA-79 CVCL_6608 Neuroblastoma Homo sapiens
CHLA-119 CVCL_A055 Neuroblastoma Homo sapiens
CHLA-90 CVCL_6610 Neuroblastoma Homo sapiens
CHLA-172 CVCL_A056 Neuroblastoma Homo sapiens
                    Experimental
                    Result(s)
Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. The combination caused reduction in the expression of G(2)/M proteins (cyclin B1, Mad2, MPM2) in 2 cell lines with mt TP53 but not in those with wt TP53.
References
Reference 1 ClinicalTrials.gov (NCT00278330) Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia U.S. National Institutes of Health.
Reference 2 ClinicalTrials.gov (NCT00324480) Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors U.S. National Institutes of Health.
Reference 3 Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Mol Cancer Ther. 2010 Dec;9(12):3289-301.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China